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Introduction
Cardiac troponins are routinely used to rule in or rule out acute coronary syndrome in the emergency
department (ED). Among patients with symptomatic atrial fibrillation (AF), mildly elevated troponin
levels are common but rarely caused by type 1 myocardial infarction.1 We aimed to investigate the
association of heart rate with high-sensitivity cardiac troponin T (hs-cTn T) levels in patients admitted
to the ED for AF.
Methods
The Ethics Committee of the Hospital District of Southwest Finland approved this cohort study and deter-
mined that written informed consent was not required because of the retrospective nature of the study.
This study is reported following the Strengthening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) guideline for the reporting of observational studies. The Tropo-AF study1 aimed to investigate
the factors associated with minor hs-cTn T elevations (<0.1 ng/mL; to convert to micrograms per liter,
multiply by 1) in 2911 patients with AF at the ED; 501 patients from the Tropo-AF study fulfilled the inclusion
criteria for this cohort study: at least 2 hs-cTn T samples within 72 hours and principal discharge diagnosis
of AF. The primary outcome measure was peak hs-cTn T serum level within 72 hours of ED admission.
Categorical variables were compared using Fisher exact test or Mantel-Haenszel linear-by-linear association
test for trend, and continuous variables were compared between groups using Mann-Whitney U test. P
values were 2-sided, and significance was set at P < .05. Statistical evaluation was conducted from January
2020 to April 2020 using statistical software SPSS for Windows version 25.0 (IBM) and R version 3.6.1 (R
Project for Statistical Computing) (eAppendix in the Supplement).
Results
A total of 501 patients (median [interquartile range] age, 75.6 [66.6-82.3] years; 262 [52.3%] wom-
en) were included in analysis (Table). In multiple linear regression analysis (Akaike information crite-
rion, 4319.44), increase in peak hs-cTn T level was independently associated with a higher heart rate
(β = 0.194; P < .001). Other factors independently associated with peak hs-cTn T levels were age
(β = 0.141; P = .004), low hemoglobin levels (β = 0.142; P = .001), decreasing estimated glomerular
filtration rate (β = 0.130; P = .004), diabetes (β = 0.129; P = .001), heart failure (β = 0.124; P = .002),
new-onset AF (β = 0.155; P < .001), and absence of palpitation (β = 0.152; P < .001).
Multiple logistic regression revealed that the association of heart rate with elevated hs-cTn T
level (>0.014 ng/mL) was limited to patients in the 2 groups with the highest heart rates (heart rate,
125-139 beats per minute [bpm]: adjusted odds ratio, 2.03; 95% CI, 1.05-3.90; P = .03; heart
rate 140 bpm: adjusted odds ratio, 4.05; 95% CI, 1.80-9.12; P = .001) compared with patients with
admission heart rate less than 90 bpm. The generalized additive model confirmed a nonlinear
association between peak hs-cTn T and admission heart rate (Figure, A). While 68 of 85 patients with
CHA2DS2-VASc score 4 or higher and heart rate 125 bpm or higher (80.0%) had elevated hs-cTn T
levels, only 17 of 48 patients with CHA2DS2-VASc score at least 1 and heart rate less than 125 bpm
(35.4%) had elevated hs-cTn T levels (P for overall trend < .001) (Figure, B).
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Patients with coronary artery disease had higher median (interquartile range) peak hs-cTn T
levels (0.024 ng/mL [0.014-0.045]) compared with patients without known disease (0.019 [0.011-
0.035] ng/mL; P = .001). The peak hs-cTn T level was independently associated with higher heart
rate in patients with known coronary artery disease (β = 0.168; P = .04) and those without
(β = 0.205; P < .001; P for interaction = .66).
Of 501 patients, 69 patients (13.8%) had a dynamic change of more than 50% in hs-cTn T level.
Multiple logistic regression analysis showed that heart rate 140 bpm or greater was significantly
associated with a change of more than 50% in hs-cTn T level (adjusted odds ratio, 4.61; 95% CI, 1.62-
13.14; P = .004).
Table. Baseline Characteristics and Follow-up Data
Characteristic
No. (%)
P valueOverall (N = 501)
Heart rate, bpm
<125 (n = 299) ≥125 (n = 202)
Age, median (IQR), y 75.6 (66.6-82.3) 76.0 (66.7-82.4) 75.0 (66.3-82.1) .41
Women 262 (52.3) 142 (47.5) 120 (59.4) .01
CHA2DS2-VASc score, median (IQR) 3 (2-4) 3 (2-4) 3 (2-4) .43
Congestive heart failure 45 (9.0) 29 (9.7) 16 (7.9) .53
Hypertension 318 (63.5) 192 (64.2) 126 (62.4) .71
Diabetes mellitus 93 (18.6) 60 (20.1) 33 (16.3) .35
Prior stroke/TIA 60 (12.0) 37 (12.4) 23 (11.4) .78
Coronary artery diseasea 131 (26.1) 85 (28.4) 46 (22.8) .18
Prior myocardial infarction 67 (13.4) 42 (14.0) 25 (12.4) .69
Prior PCI or CABG 66 (13.2) 37 (12.4) 29 (14.4) .59
Hypercholesterolemia 193 (38.5) 119 (39.8) 74 (36.6) .51
Current smoker 28 (5.6) 13 (4.3) 15 (7.4) .17
Active malignancy 26 (5.2) 14 (4.7) 12 (5.9) .54
Types of AF
Permanent or persistent 91 (18.2) 69 (23.1) 22 (10.9) .001
Paroxysmal 280 (55.9) 165 (55.2) 115 (56.9) .72
New-onset 130 (25.9) 65 (21.7) 65 (32.2) .01
Antithrombotic therapy
Antiplatelet therapy 120 (24.0) 74 (24.7) 46 (22.8) .67
Acetylsalicylic acid 108 (21.6) 70 (23.4) 38 (18.8) .23
Clopidogrel 14 (2.8) 5 (1.7) 9 (4.5) .10
Anticoagulation 269 (53.7) 173 (57.9) 96 (47.5) .03
Antiarrhythmic agents 341 (68.1) 219 (73.2) 122 (60.4) .003
β blockers 332 (66.3) 214 (71.6) 118 (58.4) .003
Symptoms
Chest pain 99 (19.8) 57 (19.1) 42 (20.8) .65
Dyspnea 133 (26.5) 79 (26.4) 54 (26.7) >.99
Palpitations 250 (49.9) 148 (49.5) 102 (50.5) .86
Heart rate at admission,
median (IQR), bpmb
116 (95-135) 98 (83-113) 138 (131-146) <.001
Laboratory variables, median (IQR)
Peak hs-cTn T at 72 h, ng/mL 0.020
(0.012-0.038)
0.018
(0.011-0.032)
0.026
(0.014-0.045)
<.001
Systolic blood pressure, mm Hgc 136 (120-150) 136 (121-152) 135 (118-149) .29
Hemoglobin, g/dL 13.8 (12.5-14.8) 13.8 (12.5-14.9) 13.7 (12.6-14.7) .68
C-reactive protein, mg/dLd 0.3 (0.2-1.0) 0.3 (0.2-0.8) 0.4 (0.2-1.1) .01
eGFR, mL/min/1.73 m2e 66.6 (51.3-82.4) 66.1 (50.5-80.6) 67.8 (53.7-84.1) .24
<60 186 (37.1) 115 (38.5) 71 (35.1) .51
End points at 1 y
All-cause mortality 41 (8.2) 19 (6.4) 22 (10.9) .10
Myocardial infarction 4 (0.8) 3 (1.0) 1 (0.5) .65
Stroke 4 (0.8) 4 (1.3) 0 (0) .15
Abbreviations: AF, atrial fibrillation; bpm, beats per
minute; CABG, coronary artery bypass graft; eGFR,
estimated glomerular filtration rate; hs-cTn T, high-
sensitivity cardiac troponin T; IQR, interquartile range;
PCI, percutaneous coronary intervention; TIA,
transient ischemic attack.
SI conversion factors: To convert hs-cTn T to
micrograms per liter, multiply by 1; hemoglobin to
grams per liter, multiply by 10; C-reactive protein to
milligrams per liter, multiply by 10.
a Defined as a diagnosis of coronary disease, history of
myocardial infarction, percutaneous coronary
intervention, or coronary artery bypass graft surgery.
b Heart rate was determined from the first 12-lead
electrocardiogram obtained during the emergency
department visit.
c Missing data on systolic blood pressure in 60
patients (12%).
d Missing data on C-reactive protein in 85
patients (17%).
e Calculated using the Chronic Kidney Disease
Epidemiology Collaboration equation.
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Discussion
This cohort study found that high ventricular heart rate was significantly associated with troponin
release in patients admitted to the ED primarily for symptomatic AF. The association of heart rate
with hs-cTn T release was nonlinear and became evident above the heart rate threshold of 125 bpm.
Persistent mild elevation of troponin levels is a common finding in AF, but the underlying
etiopathogenesis remains unclear.1,2 Old age and multiple comorbidities were associated with minor
troponin elevations in patients with AF independent of heart rate. This study’s findings suggest that
inadequate ventricular rate control in the acute setting was associated with increased troponin T
levels. Patients with elevated troponin levels were not at increased cardiovascular risk, and the
magnitude of troponin release was not associated with the presence of known coronary artery
disease or chest pain. Similarly, elevated troponin levels can be observed after marathon racing,
supraventricular tachycardia, or rapid atrial pacing in individuals with normal coronary arteries and
even in individuals without biochemical evidence of myocardial ischemia.3-6
Limitations of this study include its retrospective design, small sample size, and determination
of heart rate from single admission electrocardiogram. Nevertheless, these results suggest that high
ventricular heart rate at admission was independently associated with troponin release in patients
with AF. The effect of ventricular heart rate should be taken into consideration in the differential
diagnosis of patients with AF and increased troponin levels.
ARTICLE INFORMATION
Accepted for Publication: July 6, 2020.
Published: September 22, 2020. doi:10.1001/jamanetworkopen.2020.16880
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Pouru J-P
et al. JAMA Network Open.
Corresponding Author: K.E. Juhani Airaksinen, MD, PhD, Heart Center, Turku University Hospital and University
of Turku, Hämeentie 11, PO Box 52, FIN‐20521 Turku, Finland (juhani.airaksinen@tyks.fi).
Author Affiliations: Heart Center, Turku University Hospital and University of Turku, Turku, Finland (Pouru,
Jaakkola, Biancari, Kiviniemi, Nuotio, Airaksinen); Research Unit of Cardiac Surgery, Anesthesia and Critical Care,
University of Oulu, Oulu, Finland (Biancari); Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland
(Biancari); Department of Acute Internal Medicine, Turku University Hospital and University of Turku, Turku,
Figure. Association of High-Sensitivity Cardiac Troponin T (hs-cTn T) Level With Heart Rate
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A. Generalized additive model (adjusted R2 = 0.249; Akaike information criterion,
4232.21; estimated df = 3.04; P < .001). Adjustments were made for age, hemoglobin,
estimated glomerular filtration rate, diabetes, congestive heart failure, new-onset atrial
fibrillation, and palpitation symptoms. Shaded region indicates 95% CIs of the smooth
function (continuous line) with the uncertainty of the overall mean. B. Elevated hs-cTn T
was defined as higher than 0.014 ng/mL (to convert to micrograms per liter, multiply by
1). bpm indicates beats per minute.
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